How to buy Beam Therapeutics stock

Beam Therapeutics Inc is a biotechnology business based in the US. Beam Therapeutics shares (BEAM) are listed on the NASDAQ and all prices are listed in US Dollars. Beam Therapeutics employs 166 staff and has a trailing 12-month revenue of around USD$24,000.

How to buy shares in Beam Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Beam Therapeutics. Find the stock by name or ticker symbol: BEAM. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Beam Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Beam Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Beam Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Beginners

Robinhood

Our top pick for

Active investors

Webull

Our top pick for

Building a portfolio

Sofi Invest

How we chose our top picks

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

• Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
• Our pick for active investors. We picked Webull for this category because its platform offers features that cater to advancing investors as well as beginners. The desktop app is outfitted with an extensive set of research tools, the mobile app gets high grades from users and traders can test strategies with a paper-trading feature.
• Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.

What's in this guide?

1. BEAM shares summary
2. Compare share dealing platforms
3. Is BEAM stock a buy or sell?
4. Stock performance over time
5. Can I short BEAM shares?
6. Beam Therapeutics's financials
7. Does Beam Therapeutics pay a dividend?
8. Other common questions

Beam Therapeutics share price

Use our graph to track the performance of BEAM stocks over time.

Beam Therapeutics shares at a glance

• Key figures

Information last updated 2021-03-03.

52-week range	USD$13 - USD$126.9
50-day moving average	USD$102.243
200-day moving average	USD$58.4856
Wall St. target price	USD$102.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.0086

Buy Beam Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee	Signup bonus
Robinhood		$0	Stocks, Options, ETFs, Gold/Commodities	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Webull		$0	Stocks, Options, ETFs	$0	0%	Get two free stock valued between $2.50 and $250 Open an account	Margin financing rates start at 3.99%. No monthly subscription fees for margin.	Go to site More Info		loading Fetching your data...
TradeStation		$0	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract		$50 Deposit qualifying assets of $5,000+	A platform built for all kinds of traders and all styles of trading	Go to site More Info		loading Fetching your data...
Tastyworks		$0	Stocks, Options, Cryptocurrency	Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg Futures: $2.50/contract to open, $0 to close	0%	Get 100 shares of stock (worth $1 to $6 a share) Open and fund a new cash or margin account with $2,000+	Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options, Mutual funds	$0 + $0.65/contract, $1 minimum	0%	N/A	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Beam Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Beam Therapeutics Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Shorting Beam Therapeutics shares

There are currently 5.3 million Beam Therapeutics shares held short by investors – that's known as Beam Therapeutics's "short interest". This figure is 4.4% down from 5.6 million last month.

There are a few different ways that this level of interest in shorting Beam Therapeutics shares can be evaluated.

Beam Therapeutics's "short interest ratio" (SIR)

Beam Therapeutics's "short interest ratio" (SIR) is the quantity of Beam Therapeutics shares currently shorted divided by the average quantity of Beam Therapeutics shares traded daily (recently around 1.0 million). Beam Therapeutics's SIR currently stands at 5.13. In other words for every 100,000 Beam Therapeutics shares traded daily on the market, roughly 5130 shares are currently held short.

However Beam Therapeutics's short interest can also be evaluated against the total number of Beam Therapeutics shares, or, against the total number of tradable Beam Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Beam Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Beam Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.1268% of the tradable shares (for every 100,000 tradable Beam Therapeutics shares, roughly 127 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Beam Therapeutics.

Find out more about how you can short Beam Therapeutics stock.

Beam Therapeutics overview

Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of Beam Therapeutics is owned by insiders or institutions?

  Currently 16.843% of Beam Therapeutics shares are held by insiders and 65.505% by institutions.

• How many people work for Beam Therapeutics?

  Latest data suggests 166 work at Beam Therapeutics.

• When does the fiscal year end for Beam Therapeutics?

  Beam Therapeutics's fiscal year ends in December.

• Where is Beam Therapeutics based?

  Beam Therapeutics's address is: 26 Landsdowne Street, Cambridge, MA, United States, 02139

• What is Beam Therapeutics's ISIN number?

  Beam Therapeutics's international securities identification number is: US07373V1052

• What is Beam Therapeutics's CUSIP number?

  Beam Therapeutics's Committee on Uniform Securities Identification Procedures number is: 073730103